Category Archives: News
DEFINING LONG-TERM QUALITY OF LIFE AND FUNCTIONAL OUTCOMES AFTER REDO ILEAL POUCH ANAL ANASTOMOSIS: WHAT SHOULD PATIENTS AND PROVIDERS EXPECT?
Pouch failure after restorative proctocolectomy with ileal pouch anal anastomosis (IPAA) occurs in up to 15% of cases. A redo pouch procedure can be offered to maintain intestinal continuity after pouch failure, but little is known on quality of life (… Continue reading
DEVELOPMENT AND VALIDATION OF A PATIENT-REPORTED OUTCOME MEASURE FOR CROHN’S DISEASE: THE CROHN’S DISEASE-HEALTH INDEX (CD-HI), A FULLY VALIDATED TOOL TO BOLSTER CLINICAL TRIAL AND RESEARCH INFRASTRUCTURE
To bolster Crohn’s disease (CD) clinical trial and research infrastructure through the development and validation of a sensitive, multifactorial, disease-specific, patient-reported outcome measure (PRO) for patient monitoring in therapeutic trials of C… Continue reading
PRIMARY EOSINOPHILIC COLITIS WITH CONCOMITANT NEWLY DIAGNOSED INFLAMMATORY BOWEL DISEASE – A DIAGNOSITIC CONUNDRUM
Eosinophilic colitis (EC) is a rare primary condition characterized by eosinophilic infiltration of the colon in the absence of secondary causes. Affecting only 0.003% of people in the United States, clinical manifestations of the disease can range fro… Continue reading
ARTHRITIS AND ARTHRALGIA AS EXTRAINTESTINAL MANIFESTATIONS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE TREATED WITH VEDOLIZUMAB: A META-ANALYSIS
Vedolizumab is a humanized gut selective drug that specifically targets α4β7 integrin and has been used successfully in the treatment of Inflammatory Bowel Disease (IBD). Although Vedolizumab is an effective treatment for IBD and acts specifically on t… Continue reading
EFFICACY OF UPADACITINIB IN PATIENTS PREVIOUSLY TREATED WITH TOFACITINIB FOR THE MANAGEMENT OF ULCERATIVE COLITIS
Tofactinib is a JAK inhibitor that targets mainly JAK 1 and JAK3 approved to treat Ulcerative Colitis (UC) in 2018. The JAK inhibitor Upadacitinib (upa) was recently approved to treat UC in March 2022 and has increased selectivity for JAK1. The relativ… Continue reading
METHODS TO DERIVE A MODIFIED MAYO SCORE FROM ELECTRONIC HEALTH RECORDS DATA
The modified Mayo Score (MMS), which consists of stool frequency, rectal bleeding, and endoscopic subscores, is the most commonly used method for measuring disease activity in Ulcerative Colitis (UC) patients. It is a standard outcome measure in clinic… Continue reading
INFLAMMATORY BOWEL DISEASE AND ASSOCIATED CARDIOVASCULAR DISEASE OUTCOMES: A SYSTEMATIC REVIEW
There is limited and conflicting data available regarding the Cardiovascular disease outcomes associated with Inflammatory Bowel Disease (IBD) Continue reading
SEPSIS IN THE SETTINGS OF INFLAMMATORY BOWEL DISEASE: STUDYING THE OUTCOMES OF OVER EIGHT-MILLION PATIENTS
Inflammatory bowel disease (IBD) is associated with increased risk of infections, attributed to the nature of the disease itself, and the use of immunosuppressive agents in these patients as well. However, the impact of IBD on patients with sepsis is p… Continue reading
HOSPITALIZATION TRENDS IN INFLAMMATORY BOWEL DISEASE PATIENTS WITH POUCHITIS: A POPULATION-BASED STUDY
Pouchitis is a complication of total colectomy and ileal pouch-anal anastomosis for ulcerative colitis that can lead to hospitalization. We aimed to assess trends of hospitalization rates and health care utilization in patients with pouchitis from 2010… Continue reading
ASSESSMENT OF THE IMMUNE CELL LANDSCAPE IN INFLAMMATORY BOWEL DISEASE
Inflammatory Bowel Disease (IDB) is a chronic and sometimes refractory group of gastrointestinal conditions that can cause enormous medical and socioeconomic burdens. [1] Both, innate and adaptive immune cells play a crucial role in the pathogenesis of… Continue reading